SCHEDULE 13G: Akari Therapeutics: Dr. Hoyoung Huh Discloses 15.5% Beneficial Ownership Stake

Dr. Hoyoung Huh has reported a significant beneficial ownership of 15.5% in Akari Therapeutics, Plc, comprising over 8.29 billion ordinary shares.

Summary

• Hoyoung Huh, M.D., Ph.D., has filed a Schedule 13G with the SEC, disclosing his beneficial ownership in Akari Therapeutics, Plc.
• The filing indicates beneficial ownership of 8,294,508,000 Ordinary Shares of Akari Therapeutics, Plc.
• This stake represents 15.5% of the company's total 53,186,919,523 Ordinary Shares issued and outstanding as of February 14, 2025.
• Dr. Huh's ownership includes 7,605,994,000 Ordinary Shares directly held, 469,600,000 Ordinary Shares from options exercisable within 60 days, and 218,914,000 Ordinary Shares held by Hannol Ventures LLC, where Dr. Huh is the sole member.
• Additionally, Dr. Huh holds warrants to purchase 103,482,000 Ordinary Shares but disclaims beneficial ownership of these warrants and their underlying securities to the extent that exercise would exceed a 9.99% beneficial ownership limitation.
• The securities were not acquired for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a significant beneficial ownership stake by a key individual, which can be seen as a positive sign of alignment with shareholder interests. However, it is a routine disclosure and does not contain operational or financial performance updates.

Positives

• A key individual, Dr. Hoyoung Huh, holds a substantial 15.5% beneficial ownership stake, which may signal strong insider confidence in Akari Therapeutics' future.
• The significant ownership percentage aligns the interests of this major shareholder with the long-term success of the company.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides increased transparency regarding a significant insider stake, potentially signaling confidence in the company's future.

Key Dates

Keywords

Akari Therapeutics, Hoyoung Huh, Schedule 13G, beneficial ownership, ordinary shares, ADSs, insider ownership, equity stake, SEC filing